Test your knowledge of the key elements and outcomes of the highly buzzed about REDUCE-IT trial with this 5-question quiz.
Concern over the persistent high rate of cardiovascular (CV) events among patients on preventive treatment and the prevalence of residual CV risk even among patients receiving appropriate statin treatment has long driven research to discover an effective adjunctive therapy.REDUCE-IT was a phase 3, randomized, double-blind, placebo-controlled trial that compared icosapent ethyl with placebo in the reduction of CV events.This short quiz tests your knowledge of key trial elements and outcomes.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.